ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Valve disease

November 6, 2019
Gudala and associates performed a literature review of 108 patients who sustained left ventricular rupture following mitral valve replacement. The incidence in pooled data was 0.72%. The authors expounded on the mechanisms, classification, repair techniques, and treatment outcomes of this dreadful complication.
November 2, 2019
Participation in a post-discharge rehabilitation program after valve surgery was associated with a 34% relative decrease in hospitalization during the first year and a 61% relative decrease in mortality at one year.
October 12, 2019
The association of cardiovascular events and all-cause mortality with optimism was assessed in this meta-analysis. Optimism was associated with a decreased risk of cardiovascular events (ROR 0.65) and a decrease in all-cause mortality (RR 0.86). Mechansims have yet to be identified.
October 12, 2019
Excellent document from the EACTS, STS, and AATS emphasizing the importance of standardization of prosthetic heart valve labeling.
October 10, 2019
Reporting of postmarket outcomes for the Sapien 3 and Mitraclip devices frequently misclassified patient deaths as device malfunction or other outcomes. Misclassification for Sapien 3 involved 17.5% of patient deaths, and involved 24.7% of patient deaths for Mitraclip.
October 8, 2019
An interesting pilot experiment on attempting to quantify the optimum disposition of neochordae in transapical intervention for severe mitral regurgitation.
October 1, 2019
This video demonstrates a transaxillary direct access approach for mitral valve repair, with ultrafast-track anesthesia.
September 11, 2019
This video demonstrates a ministernotomy for aortic valve replacement.
August 29, 2019
Using an approach that minimizes valve depth relative to the membranous septum, the authors reduced the need for permanent pacemaker placement to a reliable and predictable 3% compared to the accepted standard of 10%.
August 16, 2019
The FDA-approved use of TAVR has now expanded to low-risk patients with severe aortic stenosis.  This includes both Edwards Lifesciences' Sapien 3 and Sapien 3 Ultra as well as Medtronic's  Evolut R and Evolut PRO.   

Pages